ウイルスベクター・プラスミドDNA製造市場：タイプ別、細胞株別、トランスフェクション別、適応症別、ワークフロー別、用途別、エンドユーザー別-2025-2030年世界予測

ウイルスベクター・プラスミドDNA製造市場は、2023年に15億米ドルと評価され、2024年には18億8,000万米ドルに達すると予測され、CAGR 25.34％で成長し、2030年には73億2,000万米ドルに達すると予測されています。

ウイルスベクターとプラスミドDNAの製造部門は、遺伝子治療、ワクチン、細胞治療の需要増加に牽引され、バイオ医薬品において極めて重要な役割を果たしています。この分野には、細胞内に遺伝物質を送り込むためのツールであるウイルスベクターや、遺伝子治療やDNAワクチン製造のテンプレートとなるプラスミドDNAの製造が含まれます。このような製造は、遺伝性疾患やがん治療の増加、特にCOVID-19をきっかけとしたワクチン開発への最近のスポットライトにより不可欠となっています。用途は遺伝子治療、ワクチン開発、さらには農業バイオテクノロジーの強化にまで及ぶ。この分野は、バイオテクノロジー企業、研究機関、製薬会社などのエンドユーザーを重点的にサポートしています。市場成長に影響を与える主な要因としては、遺伝子工学技術の進歩、バイオテクノロジー研究への資金提供の増加、革新的な治療法の迅速な導入を促進する規制当局の承認などが挙げられます。特に個別化医療においては、スケーラブルな製造プロセスや、バイオテクノロジー企業と製造受託機関（CMO）のコラボレーションに機会が溢れています。課題としては、製造コストの高さ、厳しい規制の枠組み、大規模遺伝子治療製造の複雑さなどが挙げられます。また、遺伝子組換えをめぐる潜在的な安全性への懸念や倫理的配慮からも限界が生じる。こうした課題にもかかわらず、特にコスト削減と効率向上のためのプロセスの最適化と自動化において、技術革新に有利な分野があります。CRISPR技術と次世代シーケンサーへの投資は、遺伝子治療で達成可能なことの限界を押し広げることもできます。さらに、強固なサプライチェーンの枠組みを構築することで、生産のボトルネックを大幅に緩和することができます。急速な技術の進歩と規制環境によって特徴づけられる市場のダイナミックな性質は、最先端の治療法を活用しようとする利害関係者にとって、課題であると同時にチャンスでもあります。急速に進化するこの業界で持続的な成長を遂げ、インパクトのあるブレークスルーをもたらすためには、複雑な規制状況をうまく切り抜けながら、責任を持ってこうしたイノベーションを受け入れることが鍵となると思われます。

市場力学：急速に進化するウイルスベクター・プラスミドDNA製造市場の主要市場インサイトを公開

ウイルスベクター・プラスミドDNA製造市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の遺伝子治療臨床試験の増加
  • 分子生物学技術の進歩
• 市場抑制要因
  • ウイルスベクターとプラスミドDNA溶液の製造コストの高さ
• 市場機会
  • 新規ウイルスベクター＆プラスミドDNAソリューションのイントロダクションの増加
  • 個別化医療への投資の増加
• 市場の課題
  • 遺伝子治療製品の安全性と有効性に関する懸念

ポーターのファイブフォース：ウイルスベクター・プラスミドDNA製造市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ウイルスベクター・プラスミドDNA製造市場における外部からの影響の把握

外部マクロ環境要因は、ウイルスベクター・プラスミドDNA製造市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ウイルスベクター・プラスミドDNA製造市場における競合情勢の把握

ウイルスベクター・プラスミドDNA製造市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスウイルスベクター・プラスミドDNA製造市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ウイルスベクター・プラスミドDNA製造市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で遺伝子治療の臨床試験が増加
    • 分子生物学技術の進歩
  • 抑制要因
    • ウイルスベクターおよびプラスミド DNAソリューションの製造コストが高い
  • 機会
    • 新しいウイルスベクターとプラスミドDNAソリューションのイントロダクションが増加
    • 個別化医療への投資増加
  • 課題
    • 遺伝子治療製品の安全性と有効性に関する懸念
• 市場セグメンテーション分析
  • 細胞株：制御された実験室環境でのin vitro細胞株の使用の増加
  • タイプ：遺伝物質を細胞に送達するためのプラスミド DNA製造の必要性の高まり
  • トランスフェクション：遺伝子治療と医薬品開発における安定トランスフェクションの人気の高まり
  • エンドユーザー：次世代ワクチンの開発と製造のために、製薬会社とバイオ医薬品会社全体でウイルスベクターとプラスミド DNAの可能性を拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 ウイルスベクター・プラスミドDNA製造市場：タイプ別

• プラスミドDNA
• ウイルスベクター
  • アデノ随伴ウイルス
  • アデノウイルス
  • レンチウイルス

第7章 ウイルスベクター・プラスミドDNA製造市場細胞株別

• 試験管内
• 生体内

第8章 ウイルスベクター・プラスミドDNA製造市場トランスフェクション別

• 安定したトランスフェクション
• 一過性トランスフェクション

第9章 ウイルスベクター・プラスミドDNA製造市場適応症別

• がん
• 遺伝性疾患
• 感染症

第10章 ウイルスベクター・プラスミドDNA製造市場：ワークフロー別

• 下流処理
  • 充填仕上げ
  • 精製
• 上流処理
  • ベクター増幅と拡張
  • ベクター回収/収穫

第11章 ウイルスベクター・プラスミドDNA製造市場：用途別

• 細胞療法
• 遺伝子治療
• ワクチン学

第12章 ウイルスベクター・プラスミドDNA製造市場：エンドユーザー別

• 製薬・バイオ医薬品企業
• 調査機関

第13章 南北アメリカのウイルスベクター・プラスミドDNA製造市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第14章 アジア太平洋地域のウイルスベクター・プラスミドDNA製造市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第15章 欧州・中東・アフリカのウイルスベクター・プラスミドDNA製造市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第16章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 味の素株式会社、フォージ・バイオロジクス社を6億2,000万米ドルで買収
  • Genezen、ウイルスベクターの開発・製造能力拡大のため1,850万米ドルの成長資本を確保
  • CCRMはMembioと提携し、細胞および遺伝子治療用のウイルスベクターの生産を効率化します

企業一覧

• Charles River Laboratories International, Inc.
• GE HealthCare Technologies, Inc.
• Biovian Oy
• c-LEcta GmbH
• Batavia Biosciences B.V.
• Thermo Fisher Scientific Inc.
• Takara Bio Inc.
• Avid Bioservices, Inc.
• Wuxi AppTec Co., Ltd.
• PerkinElmer Inc.
• REGENXBIO Inc.
• Lonza Group Ltd.
• Advanced BioScience Laboratories, Inc.
• Miltenyi Biotec B.V. & Co. KG
• Genezen Laboratories, Inc.
• FILTROX AG
• Genezen
• Merck KGaA
• Akron Biotech
• uniQure N.V.
• Kaneka Eurogentec S.A.
• BioNTech IMFS GmbH
• Creative Biogene
• Forge Biologics By Ajinomoto Co., Inc.
• Spark Therapeutics, Inc.
• FUJIFILM Diosynth Biotechnologies Inc.
• GeneOne Life Science, Inc.

LIST OF FIGURES

• FIGURE 1. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 19. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 23. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 28. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 29. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET DYNAMICS
• TABLE 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STABLE TRANSFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSIENT TRANSFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENETIC DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY FILL-FINISH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VECTOR AMPLIFICATION & EXPANSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VECTOR RECOVERY/HARVESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 73. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 74. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 75. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 77. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 78. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 79. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. CANADA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 102. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 104. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 113. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 115. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 116. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 125. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 126. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 127. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 128. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 129. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 130. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 131. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. CHINA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 135. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 136. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 137. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 139. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 140. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 141. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. INDIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 145. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 146. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 147. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 150. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 155. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 156. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 157. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 158. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 159. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 160. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 163. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 165. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 166. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 167. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 169. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 170. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 173. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 175. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 176. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 177. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 179. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 180. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 185. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 186. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 187. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 189. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 190. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 193. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 194. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 195. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 196. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 197. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 198. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 203. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 204. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 205. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 206. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 207. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 208. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 209. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 210. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 213. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 214. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 215. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 216. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 217. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 218. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 219. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 220. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 223. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 224. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 225. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 226. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 227. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 228. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 229. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 230. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 233. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 234. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 235. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 236. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 237. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 244. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 245. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 246. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 247. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 248. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 249. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 250. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 251. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 252. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 254. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 255. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 256. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 257. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 258. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 259. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 260. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 261. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 262. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 264. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 265. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 266. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 267. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 268. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 269. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 270. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 271. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 272. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 274. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 275. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
• TABLE 276. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY CELL LINE, 2018-2030 (USD MILLION)
• TABLE 277. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TRANSFECTION, 2018-2030 (USD MILLION)
• TABLE 278. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 279. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
• TABLE 280. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 281. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
• TABLE 282. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 284. GERMANY VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 285. GERMANY VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD

The Viral Vector & Plasmid DNA Manufacturing Market was valued at USD 1.50 billion in 2023, expected to reach USD 1.88 billion in 2024, and is projected to grow at a CAGR of 25.34%, to USD 7.32 billion by 2030.

The viral vector and plasmid DNA manufacturing sector plays a pivotal role in biopharmaceuticals, driven by the increasing demand for gene therapies, vaccines, and cell therapies. It encompasses the production of viral vectors, which are tools for delivering genetic material into cells, and plasmid DNA, which serves as a template for gene therapy and DNA vaccine production. Such manufacturing is essential due to the rise in genetic disorders, cancer therapies, and the recent spotlight on vaccine development, particularly in the wake of COVID-19. Applications span across gene therapy, vaccine development, and even in enhancing agricultural biotechnologies. The sector prominently supports end-users such as biotech companies, research institutes, and pharmaceutical firms. Key factors influencing market growth include advancements in genetic engineering techniques, increased funding for biotech research, and regulatory approvals facilitating the faster introduction of innovative therapies. Opportunities abound in scalable manufacturing processes and collaboration between biotech companies and Contract Manufacturing Organizations (CMOs), especially for personalized medicine. Challenges include high production costs, stringent regulatory frameworks, and complexity in large-scale gene therapy production. Limitations also arise from potential safety concerns and ethical considerations surrounding genetic modifications. Despite these challenges, there are lucrative areas for innovation, notably in process optimization and automation to reduce costs and improve efficiency. Investment in CRISPR technology and next-gen sequencing can also push the boundary of what's achievable in genetic therapy. Moreover, developing robust supply chain frameworks can significantly alleviate production bottlenecks. The market's dynamic nature, characterized by rapid technological advancements and regulatory environments, presents both a challenge and an opportunity for stakeholders looking to leverage cutting-edge therapies. Embracing these innovations responsibly while navigating the intricate regulatory landscape will be key for sustained growth and impactful breakthroughs in this rapidly evolving industry.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Viral Vector & Plasmid DNA Manufacturing Market

The Viral Vector & Plasmid DNA Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing number of gene therapy clinical trials worldwide
  • Growing advancement in molecular biology technologies
• Market Restraints
  • High cost of manufacturing of viral vector & plasmid DNA solutions
• Market Opportunities
  • Growing introduction of novel viral vector & plasmid DNA solutions
  • Rising investment in personalized medicine
• Market Challenges
  • Concerns regarding the safety and efficacy of gene therapy products

Porter's Five Forces: A Strategic Tool for Navigating the Viral Vector & Plasmid DNA Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Viral Vector & Plasmid DNA Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Viral Vector & Plasmid DNA Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Viral Vector & Plasmid DNA Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Viral Vector & Plasmid DNA Manufacturing Market

A detailed market share analysis in the Viral Vector & Plasmid DNA Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Viral Vector & Plasmid DNA Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Viral Vector & Plasmid DNA Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Viral Vector & Plasmid DNA Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Charles River Laboratories International, Inc., GE HealthCare Technologies, Inc., Biovian Oy, c-LEcta GmbH, Batavia Biosciences B.V., Thermo Fisher Scientific Inc., Takara Bio Inc., Avid Bioservices, Inc., Wuxi AppTec Co., Ltd., PerkinElmer Inc., REGENXBIO Inc., Lonza Group Ltd., Advanced BioScience Laboratories, Inc., Miltenyi Biotec B.V. & Co. KG, Genezen Laboratories, Inc., FILTROX AG, Genezen, Merck KGaA, Akron Biotech, uniQure N.V., Kaneka Eurogentec S.A., BioNTech IMFS GmbH, Creative Biogene, Forge Biologics By Ajinomoto Co., Inc., Spark Therapeutics, Inc., FUJIFILM Diosynth Biotechnologies Inc., and GeneOne Life Science, Inc..

Market Segmentation & Coverage

This research report categorizes the Viral Vector & Plasmid DNA Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Plasmid DNA and Viral Vector. The Viral Vector is further studied across Adeno-Associated Virus, Adenovirus, and Lentivirus.
• Based on Cell Line, market is studied across In-vitro and In-Vivo.
• Based on Transfection, market is studied across Stable Transfection and Transient Transfection.
• Based on Indication, market is studied across Cancer, Genetic Disorder, and Infectious Disease.
• Based on Workflow, market is studied across Downstream Processing and Upstream Processing. The Downstream Processing is further studied across Fill-finish and Purification. The Upstream Processing is further studied across Vector Amplification & Expansion and Vector Recovery/Harvesting.
• Based on Application, market is studied across Cell Therapy, Gene Therapy, and Vaccinology.
• Based on End User, market is studied across Pharmaceutical & Biopharmaceutical Companies and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing number of gene therapy clinical trials worldwide
    • 5.1.1.2. Growing advancement in molecular biology technologies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of manufacturing of viral vector & plasmid DNA solutions
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing introduction of novel viral vector & plasmid DNA solutions
    • 5.1.3.2. Rising investment in personalized medicine
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns regarding the safety and efficacy of gene therapy products
• 5.2. Market Segmentation Analysis
  • 5.2.1. Cell Line: Growing usage of in-vitro cell lines in controlled laboratory environments
  • 5.2.2. Type: Increasing need for plasmid DNA manufacturing to deliver genetic material into cells
  • 5.2.3. Transfection: Rising popularity of stable transfection for gene therapy and drug development
  • 5.2.4. End User: Expanding the potential of viral vectors & plasmid DNA across pharmaceutical & biopharmaceutical companies for the development and production of next-generation vaccines
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Viral Vector & Plasmid DNA Manufacturing Market, by Type

• 6.1. Introduction
• 6.2. Plasmid DNA
• 6.3. Viral Vector
  • 6.3.1. Adeno-Associated Virus
  • 6.3.2. Adenovirus
  • 6.3.3. Lentivirus

7. Viral Vector & Plasmid DNA Manufacturing Market, by Cell Line

• 7.1. Introduction
• 7.2. In-vitro
• 7.3. In-Vivo

8. Viral Vector & Plasmid DNA Manufacturing Market, by Transfection

• 8.1. Introduction
• 8.2. Stable Transfection
• 8.3. Transient Transfection

9. Viral Vector & Plasmid DNA Manufacturing Market, by Indication

• 9.1. Introduction
• 9.2. Cancer
• 9.3. Genetic Disorder
• 9.4. Infectious Disease

10. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow

• 10.1. Introduction
• 10.2. Downstream Processing
  • 10.2.1. Fill-finish
  • 10.2.2. Purification
• 10.3. Upstream Processing
  • 10.3.1. Vector Amplification & Expansion
  • 10.3.2. Vector Recovery/Harvesting

11. Viral Vector & Plasmid DNA Manufacturing Market, by Application

• 11.1. Introduction
• 11.2. Cell Therapy
• 11.3. Gene Therapy
• 11.4. Vaccinology

12. Viral Vector & Plasmid DNA Manufacturing Market, by End User

• 12.1. Introduction
• 12.2. Pharmaceutical & Biopharmaceutical Companies
• 12.3. Research Institutes

13. Americas Viral Vector & Plasmid DNA Manufacturing Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
  • 16.3.1. Ajinomoto Co., Inc. to Acquire Forge Biologics for USD 620 Million
  • 16.3.2. Genezen Secures USD 18.5 Million in Growth Equity to Expand Viral Vector Development and Manufacturing Capabilities
  • 16.3.3. CCRM Partners with Membio to Streamline Production of Viral Vectors for Cell and Gene Therapies

Companies Mentioned

• 1. Charles River Laboratories International, Inc.
• 2. GE HealthCare Technologies, Inc.
• 3. Biovian Oy
• 4. c-LEcta GmbH
• 5. Batavia Biosciences B.V.
• 6. Thermo Fisher Scientific Inc.
• 7. Takara Bio Inc.
• 8. Avid Bioservices, Inc.
• 9. Wuxi AppTec Co., Ltd.
• 10. PerkinElmer Inc.
• 11. REGENXBIO Inc.
• 12. Lonza Group Ltd.
• 13. Advanced BioScience Laboratories, Inc.
• 14. Miltenyi Biotec B.V. & Co. KG
• 15. Genezen Laboratories, Inc.
• 16. FILTROX AG
• 17. Genezen
• 18. Merck KGaA
• 19. Akron Biotech
• 20. uniQure N.V.
• 21. Kaneka Eurogentec S.A.
• 22. BioNTech IMFS GmbH
• 23. Creative Biogene
• 24. Forge Biologics By Ajinomoto Co., Inc.
• 25. Spark Therapeutics, Inc.
• 26. FUJIFILM Diosynth Biotechnologies Inc.
• 27. GeneOne Life Science, Inc.